P0920 - Prevalence of Neurologic Co-Morbidities in Patients with IBD compared to IBS and RA: A Multi-Network Population Based Study

Abdullah Mahmood, MD¹, Shaina Ailawadi, MD¹, Jaime A. Perez, PhD², Elleson G. Harper, BS¹, Edith Y. Ho, MD, MS³, Preetika Sinh, MD⁴, Vu Q. Nguyen, MD, MS⁵, Gregory Cooper, MD⁵, Jeffry Katz, MD⁵, Fabio Cominelli, MD, PhD⁵, Miguel D Regueiro, MD⁶, Emad Mansoor, MD^5
1University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, OH; ²University Hospitals Clinical Research Center, Cleveland, OH; ³Creighton University School of Medicine, Stanford, CA; ⁴Medical College of Wisconsin, Milwaukee, WI; ⁵Digestive Health Institute, University Hospitals Cleveland Medical Center, Cleveland, OH; ⁶Cleveland Clinic, Cleveland, OH

Introduction: Extraintestinal manifestations of IBD commonly affect the joints, eyes, and skin. Recent studies have looked at a potential link between IBD and the neurological system, yielding conflicting results. Our study assessed prevalence of common neurological disorders in IBD patients compared to patients with irritable bowel syndrome (IBS), and rheumatoid arthritis (RA), using a large national multicenter cohort.

Methods: We conducted a retrospective study using TriNetX, a de-identified federated database involving 89 healthcare organizations and over 125 million patients. Three cohorts aged ≥ 18 were identified: 1) CD or UC 2) RA only 3) IBS only. We collected demographic data on prevalence of concomitant neurologic co-morbidities (stroke, dementia, multiple sclerosis (MS), epilepsy, Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS) occurring after the index diagnosis. To control for potential confounding variables, we performed 1:1 greedy nearest neighbor propensity score matching, based on patient demographics and comorbid conditions. We performed independent t-tests for continuous data and chi-square tests for categorical data (presented as frequencies and percentages). We evaluated differences in outcome risk using odds ratios and 95% confidence intervals. All tests were two-tailed with an alpha level of .05.

Results: The overall prevalence of MS and ALS in IBD patients was low at 0.5% and 0.02% respectively. After matching for age, race and sex, compared to RA patients, IBD patients exhibited lower prevalence of stroke (OR 0.79 95% CI 0.77, 0.81), dementia (OR 0.88 95% CI 0.85, 0.91), MS (OR 0.85 95% CI 0.81, 0.9), epilepsy (OR 0.89 95% CI 0.87, 0.92), and PD (OR 0.9 95% CI 0.86, 0.95). Compared to IBS patients, IBD patients showed decreased prevalence of stroke (OR 0.92 95% CI 0.9, 0.95), dementia (OR 0.84 95% CI 0.81, 0.87), and PD (OR 0.78 95% CI 0.75, 0.82).

Discussion: Our findings reveal an overall low prevalence of neurologic co-morbidity in IBD compared to IBS and RA, which is reassuring. This could be due to the differing inflammatory profiles, pathophysiologic mechanisms and treatment regimens found in IBD compared to RA and IBS.



Disclosures:


Abdullah Mahmood, MD¹, Shaina Ailawadi, MD¹, Jaime A. Perez, PhD², Elleson G. Harper, BS¹, Edith Y. Ho, MD, MS³, Preetika Sinh, MD⁴, Vu Q. Nguyen, MD, MS⁵, Gregory Cooper, MD⁵, Jeffry Katz, MD⁵, Fabio Cominelli, MD, PhD⁵, Miguel D Regueiro, MD⁶, Emad Mansoor, MD⁵. P0920 - Prevalence of Neurologic Co-Morbidities in Patients with IBD compared to IBS and RA: A Multi-Network Population Based Study, ACG 2024 Annual Scientific Meeting Abstracts. Philadelphia, PA: American College of Gastroenterology.